Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study

Rousseau, Marc-Antoine; Lazennec, Jean-Yves; Catonné, Yves; Saillant, G

doi:10.1007/s00428-004-1011-7

Cited by 9 publications

(8 citation statements)

References 27 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of cells expressing cellular staining with the immunohistochemical stain for Ki-67 gives the proliferative index. The index is usually high in aggressive tumors and is regarded as a poor prognostic factor [25,26,27]. In our series, giant cells were Ki-67-negative in all cases and mononuclear cells were Ki-67-positive in various proportions of tumor cells.…”

Section: Discussionsupporting

confidence: 50%

“…This finding suggests that mononuclear cells are responsible for the proliferative activity in GCTB. Furthermore, several studies report that the Ki-67 index in recurrent cases is higher than in the primary tumor, and some studies report that there is no difference between the primary tumor and the recurrent tumor [16,26,27]. Ismail et al emphasized that Ki-67 is not a useful immunopathological marker in predicting local recurrence and lung metastasis of GCTB [25].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic value of p53 protein expression in giant cell tumor of bone

Yalçinkaya

Uğraş²,

Kabul³

et al. 2015

pjp

View full text Add to dashboard Cite

Giant cell tumor of bone (GCTB) is a benign tumor with a tendency for local recurrence. GCTB may cause lung metastases, and secondary malignant GCTB is rare. Its histological appearance does not predict local aggressiveness and/or the metastatic potential of the tumor. We aimed to investigate the prognostic value of the Ki-67 proliferative index and p53 protein expression in GCTB in predicting local recurrence, lung metastasis, and malignant transformation. We retrospectively reviewed 42 cases of GCTB. The p53 expression was positive in 20 cases. We used 10% as a cut-off value for p53 expression. In 10 cases, there were local recurrences. Lung metastases were found in three cases and malignant transformation was found in one case with classical GCTB located in the sacrum three years following diagnosis. The Ki-67 index was higher in cases with recurrence, but this difference was not statistically significant. Of the recurrent cases, two had no p53 staining while eight had moderate-to-strong staining. The staining was usually weakly positive in the non-recurrent cases. In conclusion, we believe that p53 may be used as a marker for the biological behavior of GCTB.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Prognostic value of p53 protein expression in giant cell tumor of bone

Yalçinkaya

Uğraş²,

Kabul³

et al. 2015

pjp

View full text Add to dashboard Cite

show abstract

“…This confirms that GCT results from proliferation of mononuclear cells and it is in agreement with our finding in this series that the antigen is confined to the mononuclear stromal cells in all cases. Earlier reports if increase in Ki-67 index in recurrent GCT may indicate that recurrent GCT are more aggressive than the primary tumor [7-10]. In this study the mean value of Ki-67 index of stage III GCT was 8.15.…”

Section: Discussionsupporting

confidence: 44%

“…Ki-67 was shown to correlate with the biological behaviour and risk of pulmonary metastases in a few reported cases of GCT of the bone [7]. However; there are no reported studies to identify the effectiveness of this marker to correlate with the aggressiveness and prognosis of the disease.…”

Section: Introductionmentioning

confidence: 99%

Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone

Ismail

Shamsudin

Zulmi

et al. 2010

J Exp Clin Cancer Res

View full text Add to dashboard Cite

BackgroundGiant cell tumor is an infrequent and unpredictable bony lesion. Although numerous attempts have been made to predict the behaviour of GCT, there are no definite biological or histological parameters to determine the prognosis or aggressiveness of this lesionMaterials and methodsWe analyzed Ki 67 immuno-histochemistry of 31 consecutive cases staged III giant cell tumor to determine the clinico-pathological correlation. There were 19 male patients compare to 12 females. The mean age was 33.8 years ranged from 18 to 59 years. Five cases presented with local recurrence prior to wide resection and one case had multiple recurrences there after. Six cases had pulmonary metastases. Expression of Ki 67 antigen was evaluated by immuno-histochemical staining techniques using the avidin-biotin perioxidase complex method using an LSAB2 kit (Dako, Glostrup, Denmark). The primary antibody used in this study was Ki-67 (MIB-I clone, dilution 1:25; Dako).ResultsThe mean value of Ki-67 index obtained as a percentage of 1000 background cells was 8.15 (ranged 1.00 - 20.0). The median Ki 67 index was 7.5 with standard deviation of 5.12. The Ki 67 index of recurrence tumor was 4.323 compared to 6.05 without recurrence and was not statistically significant (mean difference of 0.865 with p value in independent t test of 0.736). The Ki 67 index was also not statistically significant in the presence of pulmonary metastases with the mean value of metastases group of 6.681 compared to 2.890 without metastases (mean difference of 1.895 with p value in independent t test of 0.424).ConclusionKi 67 index is not use-full prognostic marker for aggressive type of giant cell tumor of the bone.

show abstract

“…There are differing opinions on the ability of DNA ploidy analysis and proliferation index measurement to predict prognosis. Some researchers have found that aneuploid tumours [17,18] with high proliferation indices are more likely to recur [19], while others have shown that DNA flow cytometry [20,21] and the degree of tumour cell proliferation [22] had limited utility in predicting tumour behaviour. Well documented malignant transformation in benign GCT can occur following radiotherapy [23,24].…”

Section: Discussionmentioning

confidence: 99%

Giant Cell Tumour and Central Giant Cell Reparative Granuloma of the Skull: do These Represent Ends of a Spectrum? A Case Report and Literature Review

Saw

Thomas

Gleeson

et al. 2008

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Giant cell tumour (GCT) of bone is an uncommon primary bone neoplasm typically occurring at the epiphyses of long bones in young adults. They are osteolytic neoplasms with approximate local recurrence rates of 25%, and 2% of patients develop pulmonary metastases. These tumours appear very rarely in the skull, with those few reported cases arising predominantly in the sphenoid and occasionally the temporal bones. They demonstrate benign histological features, but are locally aggressive and surgical excision is the treatment of choice. It is widely believed that giant cell tumours should be distinguished from other giant cell lesions, importantly central giant cell reparative granulomata (CGCG) which are thought to have a lower recurrence rate and for which no cases of malignant transformation or metastases have been reported. Investigators have noted that giant cell lesions in the skull bones may be unique and that GCT and CGCG may be part of a spectrum of a single disease process. We present a case of a giant cell tumour of the temporal bone which illustrates and re-emphasises this concept and review the literature on these lesions.

show abstract

Metachronous multicentric giant-cell tumor of the bone in the lower limb. Case report and Ki-67 immunohistochemistry study

Cited by 9 publications

References 27 publications

Prognostic value of p53 protein expression in giant cell tumor of bone

Prognostic value of p53 protein expression in giant cell tumor of bone

Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone

Giant Cell Tumour and Central Giant Cell Reparative Granuloma of the Skull: do These Represent Ends of a Spectrum? A Case Report and Literature Review

Contact Info

Product

Resources

About